Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 32INDUSTRY 25NIH 4NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

nilotinib 3Peripheral Blood Stem Cell Transplantation 3fludarabine phosphate 2fludarabine 2bosutinib 2Whole-Body Irradiation 2Tacrolimus 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Imatinib Mesylate 2Dasatinib 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2plerixafor 1Stem Cell Transplantation 1Saline Solution 1Polymerase Chain Reaction 1Fibroblast Growth Factor 7 1Cytogenetic Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Dasatinib × Clear all
NCT04578847 2020-10-08

READIT

National Research Center for Hematology, Russia

Phase 2 Unknown
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00895297 2011-12-07

Dasatinib

European Society for Blood and Marrow Transplantation

Phase 2 Terminated
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡